Tc-99m PYP Cardiac Amyloidosis Imaging

Q: What is a Tc-99m PYP scan used for?

Technetium-99m pyrophosphate (Tc-99m PYP) scintigraphy is used to noninvasively diagnose transthyretin cardiac amyloidosis (ATTR-CM). When a Tc-99m PYP scan shows grade 2 or 3 myocardial uptake confirmed on SPECT and a monoclonal protein (light-chain amyloidosis) has been excluded by blood and urine testing, ATTR cardiac amyloidosis can be diagnosed without an endomyocardial biopsy.

Q: Why is SPECT required for a Tc-99m PYP study?

Planar images alone cannot always distinguish true myocardial tracer retention from residual radiotracer in the blood pool overlying the heart. SPECT (ideally SPECT/CT) localizes the uptake to the myocardium versus the ventricular blood pool, markedly reduces equivocal reads, and is required by current consensus to confirm a positive study.

Q: What is the heart-to-contralateral (H/CL) ratio?

The H/CL ratio is a semiquantitative planar measure: a region of interest over the heart is divided by a mirror-image region over the contralateral chest to correct for background. An H/CL ratio of 1.5 or greater on 1-hour imaging is the commonly used threshold consistent with significant myocardial retention, though it must be interpreted together with SPECT.

Q: What is Perugini grading?

Perugini grading is a visual, semiquantitative scale comparing myocardial tracer uptake to rib (bone) uptake: grade 0 (no myocardial uptake), grade 1 (uptake less than rib), grade 2 (uptake equal to rib), and grade 3 (uptake greater than rib with reduced bone signal). Grade 2 or 3, confirmed on SPECT, is considered positive for ATTR cardiac amyloidosis.

Q: How much radiotracer is given and how long does the scan take?

A typical adult activity is about 370 MBq (10 mCi) of Tc-99m PYP administered intravenously, with planar and SPECT imaging performed at 1 hour, and optionally at 3 hours. Tc-99m has a 6-hour physical half-life and a 140 keV photon, imaged with a low-energy high-resolution collimator.

Q: Why must light-chain (AL) amyloidosis be excluded before diagnosing ATTR?

Light-chain (AL) amyloidosis can also produce myocardial Tc-99m PYP uptake and is a medical emergency requiring different, urgent treatment. A positive PYP scan is only diagnostic of ATTR when a monoclonal protein has been excluded using serum and urine immunofixation electrophoresis and serum free light-chain testing. Skipping this step risks a dangerous misdiagnosis.

Q: Can a Tc-99m PYP scan be falsely positive?

Yes. Blood-pool activity misread as myocardial uptake on planar-only imaging, recent myocardial infarction, and other causes of tracer retention can create false positives. SPECT confirmation, correct timing, quantitative H/CL measurement, and exclusion of light-chain amyloidosis are the safeguards that keep the study reliable.

Technetium-99m pyrophosphate (PYP) scintigraphy can diagnose transthyretin cardiac amyloidosis without a biopsy — but only when the acquisition is standardized, SPECT confirms the uptake is truly myocardial, and light-chain amyloidosis has been excluded. A grade 2 or 3 study read off planar images alone, without SPECT and without a monoclonal-protein screen, is one of the most consequential avoidable errors in nuclear cardiology. ^{1, 2, 3}

Introduction

For decades, cardiac amyloidosis was considered rare, hard to diagnose, and untreatable. That picture has been overturned. Transthyretin cardiac amyloidosis (ATTR-CM) is now recognized as a common and under-diagnosed cause of heart failure with preserved ejection fraction, and disease-modifying therapy has made an early, accurate diagnosis genuinely actionable. ^{1, 8}

At the center of this shift is an old radiopharmaceutical repurposed for a new job. Technetium-99m pyrophosphate — historically a bone and infarct-avid agent — turns out to bind avidly to ATTR amyloid deposits in the myocardium. Combined with exclusion of a monoclonal protein, a positive Tc-99m PYP scan can establish ATTR-CM noninvasively, replacing endomyocardial biopsy in the great majority of cases. ^{3, 4}

But the test is deceptively simple to perform and surprisingly easy to get wrong. The difference between a reliable diagnosis and a false positive comes down to physics and protocol: correct timing, the right collimator and energy window, mandatory SPECT to separate myocardium from blood pool, a properly measured heart-to-contralateral ratio, and the discipline to rule out light-chain disease first. This guide walks through each of those elements. DRPS supports nuclear cardiology and nuclear medicine programs with PET/CT and nuclear medicine physics and medical physics consulting across Florida, Maryland, Virginia, Washington DC, California, Nevada, and our other service areas.

Topic Explanation

What is cardiac amyloidosis, and where does PYP fit?

Cardiac amyloidosis is the deposition of misfolded protein fibrils in the myocardial extracellular space, causing the heart wall to thicken and stiffen and producing restrictive cardiomyopathy and heart failure. Two protein types account for roughly 95% of cases: light-chain amyloidosis (AL), driven by a plasma-cell dyscrasia, and transthyretin amyloidosis (ATTR), from age-related or hereditary instability of the transthyretin protein. ⁸

The distinction is not academic. AL is a hematologic emergency with a poor prognosis untreated, managed with chemotherapy and immunotherapy; ATTR is more chronic and treated with heart-failure management and transthyretin-stabilizing drugs. Getting the type right — and quickly — changes the entire care pathway. ^{1, 8}

Bone-avid technetium-labeled tracers (Tc-99m PYP in the United States; Tc-99m DPD and Tc-99m HMDP in Europe) concentrate in ATTR-affected myocardium far more than in AL, giving nuclear imaging a central diagnostic role. The exact mechanism is not fully established but is thought to involve binding to microcalcifications associated with the amyloid deposits. ^{3, 5}

The non-biopsy diagnostic algorithm

The landmark contribution of Tc-99m PYP imaging is the non-biopsy diagnosis. In a large multicenter cohort, grade 2 or 3 cardiac uptake of a bone-avid tracer, combined with the absence of a monoclonal protein, was highly specific for ATTR cardiac amyloidosis. ³ The consensus algorithm is therefore a two-track evaluation: ^{1, 2}

Imaging track: Tc-99m PYP planar + SPECT, graded and quantified.
Hematology track: serum and urine immunofixation electrophoresis plus serum free light-chain assay to detect a monoclonal protein.

Only when the PYP scan is positive and the monoclonal screen is negative is ATTR-CM established without biopsy. A positive scan with a monoclonal protein present requires further work-up (often biopsy) because AL must be excluded. For related quantitative context in nuclear medicine, see our overview of thyroid uptake measurement and dose calibrator quality control.

Key Technical Principles

Radiopharmaceutical and instrumentation

Tc-99m has a physical half-life of about 6.0 hours and emits a 140 keV gamma photon, imaged with a low-energy high-resolution (LEHR) collimator and a 140 keV energy window (commonly ±10%). A typical adult administered activity is approximately 370 MBq (10 mCi) of Tc-99m PYP given intravenously. The effective dose is on the order of a few millisieverts, comparable to a conventional Tc-99m bone scan; adding a low-dose CT for SPECT/CT localization contributes a modest additional dose. ^{1, 7}

Imaging is performed after an uptake interval — most commonly 1 hour, with 3-hour imaging as an option. The rationale for the delay is blood-pool clearance: at earlier times, circulating tracer overlying the heart can mimic myocardial uptake. Evidence indicates a 1-hour protocol using planar and SPECT imaging has diagnostic performance comparable to a 3-hour protocol when positivity is defined by diffuse myocardial uptake on SPECT. ⁶

Why SPECT is not optional

Planar imaging alone cannot reliably separate myocardial retention from blood-pool activity, and this is the single most important technical safeguard in the study. A bright anterior planar image can reflect tracer still in the ventricular cavity rather than in the myocardial wall. SPECT — ideally SPECT/CT — resolves the anatomy in three dimensions and localizes uptake to the myocardium versus the chamber blood pool. ^{1, 2}

The impact is measurable. In a series comparing planar and SPECT/CT interpretation, SPECT/CT reduced the rate of equivocal reads dramatically — for 1-hour imaging, from about 83% down to roughly 25% — by resolving whether apparent uptake was truly myocardial. ⁷ Current consensus reflects this by requiring SPECT to confirm a positive planar finding. The same SPECT/CT and quantification discipline that governs SPECT/CT quality control and cardiac SPECT MPI QC applies directly here.

Semiquantitative interpretation

Two complementary methods are used. Visual Perugini grading compares myocardial uptake to rib (bone) uptake, and the heart-to-contralateral (H/CL) ratio is a background-corrected planar measurement.

Perugini grade	Visual appearance	H/CL context	Interpretation
Grade 0	No myocardial uptake; normal bone uptake	H/CL typically < 1.5	Negative
Grade 1	Myocardial uptake less than rib uptake	Often around or below 1.5	Equivocal / low grade — correlate with SPECT
Grade 2	Myocardial uptake equal to rib uptake	Commonly ≥ 1.5 at 1 h	Positive for ATTR if SPECT confirms and AL excluded
Grade 3	Myocardial uptake greater than rib, with attenuated bone signal	Commonly well above 1.5	Positive for ATTR if SPECT confirms and AL excluded

The commonly used quantitative threshold is an H/CL ratio of 1.5 or greater on 1-hour imaging (a lower threshold near 1.3 is used for 3-hour imaging). In the validation work distinguishing ATTR from AL, an H/CL ratio greater than 1.5 achieved 97% sensitivity and 100% specificity for identifying ATTR cardiac amyloidosis in that cohort. ⁴ Grade and ratio must always be read together with SPECT, never in isolation. ^{1, 2, 4}

Worked example: measuring and correcting the numbers

H/CL ratio. On the 1-hour anterior planar image, a circular region of interest (ROI) is drawn over the heart and a mirror-image ROI over the contralateral chest wall. The ratio is:

H/CL = \frac{C ˉ _{heart}}{C ˉ _{contralateral}}

If the heart ROI has a mean of $\overset{ˉ}{C}_{heart} = 948$ counts/pixel and the contralateral ROI has $\overset{ˉ}{C}_{contralateral} = 600$ counts/pixel, then:

H/CL = \frac{948}{600} = 1.58

Because $1.58 \geq 1.5$ , this meets the quantitative threshold — but it is reported as positive only if SPECT confirms myocardial (not blood-pool) localization and the monoclonal screen is negative. ^{1, 4}

Activity decay. Tc-99m decay must be respected when scheduling and when interpreting count rates. With a physical half-life $T_{1/2} = 6.0 h$ , the decay constant is:

λ = \frac{ln 2}{T _{1/2}} = \frac{0.693}{6.0 h} = 0.1155 h^{- 1}

So the fraction of an administered 370 MBq dose remaining at the 1-hour image is:

A (1 h) = 370 \cdot e^{- 0.1155 \times 1} \approx 370 \times 0.891 \approx 330 MBq

and at 3 hours:

A (3 h) = 370 \cdot e^{- 0.1155 \times 3} \approx 370 \times 0.707 \approx 262 MBq

The falling activity is one reason later imaging trades blood-pool clearance against lower count statistics, and why acquisition times or thresholds differ between the 1-hour and 3-hour protocols. ⁶

Clinical Impact

A correctly performed Tc-99m PYP study changes management decisively, and an incorrectly performed one can send a patient down the wrong path entirely. The upside is large: a widely available, relatively inexpensive nuclear scan replaces an invasive biopsy for most ATTR-CM diagnoses and opens the door to disease-modifying therapy earlier in the disease course. ^{1, 3, 8}

The downside of getting it wrong is equally consequential:

Missing AL by skipping the monoclonal screen. Treating a patient as ATTR when they actually have AL delays urgent hematologic therapy for a rapidly progressive disease.
False positive from blood pool. A planar-only read that mistakes cavity activity for myocardial uptake can label a patient with amyloidosis they do not have.
False negative from timing or technique. An acquisition performed too early, with the wrong collimator, or without SPECT can under-call true disease.

Because the stakes are asymmetric and high, the imaging program's technical quality is inseparable from the clinical outcome. This is exactly the kind of study where a nuclear medicine physicist's involvement in protocol standardization, camera QC, and quantitative consistency pays off directly in diagnostic reliability. ^{1, 2, 9}

Practical Optimization Tips

1. Standardize the acquisition

Lock down administered activity, uptake time, collimator (LEHR), energy window (140 keV ±10%), planar views, and SPECT parameters so that grade and H/CL are comparable across patients and over time. Consensus and the SNMMI technical literature provide the reference protocol. ^{1, 9}

2. Always acquire SPECT

Treat SPECT (preferably SPECT/CT) as mandatory, not optional. It is the definitive step that separates myocardial retention from blood pool and slashes equivocal reads. ^{1, 7}

3. Draw H/CL ROIs consistently

Use a reproducible method for the heart and contralateral ROIs. Inconsistent ROI placement is a common source of H/CL variability; standardize ROI size and positioning and document the method.

4. Enforce the monoclonal screen

Build the serum/urine immunofixation and free light-chain testing into the diagnostic pathway so a PYP scan is never interpreted for ATTR without it. This is a systems safeguard, not just an interpretive one. ^{1, 3}

5. Common pitfalls to avoid

Reading planar images without SPECT. The leading avoidable cause of false positives. ^{1, 7}
Imaging too early. Insufficient blood-pool clearance mimics uptake; respect the uptake interval. ⁶
Ignoring recent infarction or other avid processes. Correlate with clinical history.
Treating grade 2–3 as diagnostic on its own. It is diagnostic of ATTR only with SPECT confirmation and a negative monoclonal screen. ^{1, 3}
Letting camera QC drift. Uniformity, energy-window, and center-of-rotation problems degrade SPECT localization and quantitative consistency; see gamma camera NEMA NU-1 performance testing.

Regulatory Considerations

Tc-99m PYP imaging is medical use of byproduct material, governed by NRC or Agreement State regulation, with imaging quality expectations shaped by accreditation and professional consensus. The radiopharmaceutical component falls under 10 CFR Part 35 (medical use of byproduct material), with radiation protection under 10 CFR Part 20 and program-specific guidance in NRC NUREG-1556 Volume 9. ^{10, 11}

Key frameworks to reference:

10 CFR Part 35 — medical use of byproduct material, covering authorized users, dosage determination, and the radiation safety program under which Tc-99m PYP is administered. ¹⁰
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations (Parts 1 and 2) — the standardized methods, diagnostic criteria, and appropriate-use framework for cardiac amyloidosis imaging. ^{1, 2}
SNMMI/ASNC technical and practice literature — protocol, quantification, and interpretation guidance for Tc-99m PYP. ⁹

Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States administering their own radioactive-material programs, while Washington DC and Delaware are regulated directly by the NRC. Facilities should confirm which authority issues their license and align dosage, QC, and record-keeping accordingly, coordinating with their radioactive material license support and radiation safety officer resources.

Frequently Asked Questions (FAQs)

What is a Tc-99m PYP scan used for?

Technetium-99m pyrophosphate (Tc-99m PYP) scintigraphy is used to noninvasively diagnose transthyretin cardiac amyloidosis (ATTR-CM). When a Tc-99m PYP scan shows grade 2 or 3 myocardial uptake confirmed on SPECT and a monoclonal protein (light-chain amyloidosis) has been excluded by blood and urine testing, ATTR cardiac amyloidosis can be diagnosed without an endomyocardial biopsy.

Why is SPECT required for a Tc-99m PYP study?

Planar images alone cannot always distinguish true myocardial tracer retention from residual radiotracer in the blood pool overlying the heart. SPECT (ideally SPECT/CT) localizes the uptake to the myocardium versus the ventricular blood pool, markedly reduces equivocal reads, and is required by current consensus to confirm a positive study.

What is the heart-to-contralateral (H/CL) ratio?

The H/CL ratio is a semiquantitative planar measure: a region of interest over the heart is divided by a mirror-image region over the contralateral chest to correct for background. An H/CL ratio of 1.5 or greater on 1-hour imaging is the commonly used threshold consistent with significant myocardial retention, though it must be interpreted together with SPECT.

What is Perugini grading?

Perugini grading is a visual, semiquantitative scale comparing myocardial tracer uptake to rib (bone) uptake: grade 0 (no myocardial uptake), grade 1 (uptake less than rib), grade 2 (uptake equal to rib), and grade 3 (uptake greater than rib with reduced bone signal). Grade 2 or 3, confirmed on SPECT, is considered positive for ATTR cardiac amyloidosis.

How much radiotracer is given and how long does the scan take?

A typical adult activity is about 370 MBq (10 mCi) of Tc-99m PYP administered intravenously, with planar and SPECT imaging performed at 1 hour, and optionally at 3 hours. Tc-99m has a 6-hour physical half-life and a 140 keV photon, imaged with a low-energy high-resolution collimator.

Why must light-chain (AL) amyloidosis be excluded before diagnosing ATTR?

Light-chain (AL) amyloidosis can also produce myocardial Tc-99m PYP uptake and is a medical emergency requiring different, urgent treatment. A positive PYP scan is only diagnostic of ATTR when a monoclonal protein has been excluded using serum and urine immunofixation electrophoresis and serum free light-chain testing. Skipping this step risks a dangerous misdiagnosis.

Can a Tc-99m PYP scan be falsely positive?

Yes. Blood-pool activity misread as myocardial uptake on planar-only imaging, recent myocardial infarction, and other causes of tracer retention can create false positives. SPECT confirmation, correct timing, quantitative H/CL measurement, and exclusion of light-chain amyloidosis are the safeguards that keep the study reliable.

Key Takeaways

Tc-99m PYP enables non-biopsy diagnosis of ATTR-CM when grade 2–3 uptake is confirmed on SPECT and a monoclonal protein is excluded. ^{1, 3}
SPECT is mandatory. It separates myocardial retention from blood pool and dramatically reduces equivocal reads. ^{1, 7}
Read grade and H/CL together. An H/CL ≥ 1.5 at 1 hour is the common quantitative threshold, but it is never interpreted without SPECT. ^{2, 4}
Exclude AL first. A positive scan is diagnostic of ATTR only with a negative monoclonal-protein screen. ^{1, 3}
Timing and technique matter. Correct uptake interval, LEHR collimator, energy window, and standardized ROIs keep the study reliable. ^{1, 6, 9}
Camera QC underpins quantification. Uniformity, energy-window, and SPECT calibration problems degrade both localization and H/CL consistency. ⁹

Conclusion

Tc-99m PYP scintigraphy is a rare example of an old, inexpensive nuclear medicine test being repurposed to answer a high-stakes modern question, and doing it well. Its power to diagnose transthyretin cardiac amyloidosis without a biopsy is real — but it is entirely conditional on how the study is performed and interpreted. Standardized acquisition, mandatory SPECT to defeat the blood-pool trap, disciplined H/CL and Perugini reading, and an ironclad rule to exclude light-chain amyloidosis are what separate a trustworthy diagnosis from a dangerous mistake. For nuclear cardiology programs, that reliability is built on protocol standardization and instrument quality control — the day-to-day work of a nuclear medicine physicist.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear cardiology and nuclear medicine programs performing Tc-99m PYP imaging with protocol standardization, gamma-camera and SPECT/CT quality control, quantitative consistency review, and PET/CT and nuclear medicine physics support, alongside radioactive material license support and radiation safety officer services.

DRPS serves facilities across our locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A reliable amyloid-imaging program is not just about acquiring the scan — it is about making sure every positive read is one the care team can act on with confidence.

Related Resources

References

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging. Journal of Nuclear Cardiology. 2019;26(6):2065-2123. doi:10.1007/s12350-019-01760-6. PubMed
Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology. 2020;27(2):659-673. doi:10.1007/s12350-019-01761-5. PubMed
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. doi:10.1161/CIRCULATIONAHA.116.021612. PubMed
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circulation: Cardiovascular Imaging. 2013;6(2):195-201. doi:10.1161/CIRCIMAGING.112.000132. PubMed
Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. Journal of the American College of Cardiology. 2005;46(6):1076-1084. doi:10.1016/j.jacc.2005.05.073. PubMed
Masri A, Bukhari S, Ahmad S, et al. Efficient 1-hour technetium-99m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circulation: Cardiovascular Imaging. 2020;13(2):e010249. doi:10.1161/CIRCIMAGING.119.010249. PubMed
Coskun N, Kartal MO, Erdogan AS, Tufekcioglu O, Ozdemir E. Tc-99m pyrophosphate scintigraphy for cardiac amyloidosis: concordance between planar and SPECT/CT imaging. The International Journal of Cardiovascular Imaging. 2022;38(9):2081-2088. doi:10.1007/s10554-022-02676-y. PubMed
Embry-Dierson M, Farrell MB, Schockling E, Warren J, Jerome S. Cardiac amyloidosis imaging, part 1: amyloidosis etiology and image acquisition. Journal of Nuclear Medicine Technology. 2023;51(2):83-89. doi:10.2967/jnmt.123.265415. PubMed
Jerome S, Farrell MB, Warren J, Embry-Dierson M, Schockling EJ. Cardiac amyloidosis imaging, part 3: interpretation, diagnosis, and treatment. Journal of Nuclear Medicine Technology. 2023;51(2):102-116. doi:10.2967/jnmt.123.265492. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov